Prognostic protein markers for triple negative breast cancer by Umar, A. (Arzu) et al.
Breast cancer is a mixture of biologically different disease 
entities. One of these subtypes, called triple negative, 
is associated with a poor prognosis and lack of effective 
treatment. No clinical biomarkers are available. The 
authors of this article were able to identify a set of 
prognostic proteins by comparative tissue proteomics 
using highly advanced technology. This may lead to better 
prediction of disease prognosis and the development of new 
therapies for triple negative patients.
Breast cancer is a very heterogeneous disease, consisting of 
different molecular subtypes. Women with the so-called ‘triple 
negative’ subtype of breast cancer have poor prognosis and sur-
vival compared to other subtypes due to the aggressive nature 
of these tumours and the current absence of suitable targets for 
therapy. Clearly, identification of appropriate prognostic protein 
targets for this group of patients is of vital importance. In the 
current project, we use a comparative tissue proteomics ap-
proach for the identification of prognostic protein markers for 
triple negative breast cancer.
Breast cancer affects 1:8 women throughout their lives and ac-
counts for more than 3,000 deaths annually in the Netherlands. 
Tumour cells most commonly originate from epithelial cells 
lining the milk ducts or lobules (see Figure 1A). While histopath-
ological parameters such as tumour grade, stage, and lymph 
node or distant metastasis have long been the golden standard 
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for predicting prognosis, molecular profiling has proven to be 
an important additional parameter [1]. Molecular subtypes 
of breast cancer as defined by gene expression profiling were 
initially described a decade ago as biologically distinct disease 
entities with different clinical outcomes [2,3]. 
Five subtypes  The five main observed subtypes, luminal A, 
luminal B, HER2+, normal-like, and basal were named according 
to the expression of particular genes. The majority of breast 
tumours are of the luminal A subtype, which is characterised 
by, among other things, high expression of oestrogen receptor 
(ER) and progesterone receptor (PR), preferential metastasis 
to bone, and association with a relatively good prognosis (see 
Figure 1B). Luminal B type tumours have lower expression of ER 
and/or PR, HER2+ tumours have an amplification of the human 
epidermal growth factor receptor 2 (HER2) gene, and nor-
mal-like and basal type tumours have high expression of basal 
epithelial cell type keratins, such as keratin 5 and 17, and are 
mostly characterised by the absence of ER, PR, and HER2. For 
that reason the latter group is often referred to as ‘triple nega-
tive’. More significantly, triple negative tumours preferentially 
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Breast cancer is the most commonly diagnosed malignancy in women and affects one out of eight 
women throughout their lives. Breast cancer is not just one disease. Several subtypes are revealed and 
corresponding biomarkers could potentially be used for early detection, prognosis and therapy response 
prediction.
“For one subtype called triple negative, specific markers are lacking. Triple negative in general has a poor 
prognosis and poor patient survival,” says Arzu Umar, researcher at the Department of Medical Oncology 
of the Erasmus Medical Centre in Rotterdam. A small subgroup of these patients accounts for this poor 
prognosis and group members will develop cancer in distant organs within a few years. The majority remain 
metastasis-free for longer periods of time. “We wanted to know what caused this difference and whether 
we could find clinical biomarkers to define the triple negative subtype.”  
This article describes the special technology and method the authors used to discover these biomarkers. 
“We obtained access to very advanced technology by collaboration with the American Pacific Northwest 
National Laboratory,” Umar says. This laboratory is a user facility, which is ahead of any commercially 
available technology and therefore offers unique possibilities. The researchers were able to use a custom-
made, ultra-thin and ultra-long separation column coupled to a high resolution mass spectrometer. Umar: 
“Since we were able to separate the proteins better, we could see more. If you can see more, chances are 
higher that you will identify differences and find interesting biomarkers. And so we did.”
Umar and her colleagues detected a set of more than thirty proteins that can help to divide the group of 
the triple negative cancer into one with a good and one with a poor prognosis. Umar: “Our next step is to 
validate these proteins and unravel their function in the development of a triple negative type of breast 
cancer.” In the end this may lead to better prediction of the prognosis and development of new therapies.
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metastasize to lung and brain [4] and have the worst prognosis 
compared to other subtypes (see Figure 1B). 
The majority of breast tumours (about 80 percent) are ER, PR, 
or HER2+ positive and can be effectively treated with targeted 
therapies directed against these proteins, such as hormonal 
therapies blocking production or function of oestrogens, 
and antibody or kinase inhibitor therapies blocking the HER2 
pathway. However, about 15 percent of breast tumours are 
triple negative and effective treatment is not readily available. 
Identification of protein markers that are specifically expressed 
in triple negative tumours would not only benefit proper clinical 
classification, but would provide the basis for development of 
new, targeted therapies against this aggressive type of breast 
cancer [5]. 
Two kind of triple negative  Despite a common triple nega-
tive phenotype, these tumours can clinically be defined as two 
separate groups based on disease prognosis. Within the triple 
negative subtype, 25 percent of the patients develop distant 
metastasis within three years, whereas 75 percent remain long-
Figure 1 | Breast cancer development and progression. 
A. Cross-section and haematoxylin/eosin stain of normal and cancerous 
breast tissue. 
B. Different molecular subtypes of breast cancer, preferred sites of relapse 
and prognosis.
| 15
term metastasis-free. We hypothesise that activation of differ-
ent molecular mechanisms must account for this difference in 
prognosis. It should thus be possible to identify markers that 
specifically associate with poor prognosis in patients with triple 
negative breast cancer. With NPC funding, we have performed 
comparative global proteome profiling on tumour tissues with 
the aim of identifying prognostic protein markers for triple 
negative breast cancer.
Pacific Northwest National Laboratory  In collaboration with 
Dr. Ljiljana Paša-Tolić from the Pacific Northwest National 
Laboratory (PNNL), we have previously developed a tissue 
proteomics approach for the identification of protein markers 
(see Figure 2). Our strategy involves the use of fresh frozen 
breast cancer tissue, out of which cryosections are cut, which 
are subsequently stained in a mass spectrometry-friendly man-
ner and subjected to laser capture microdissection (LCM). The 
LCM step is pivotal to enrich for epithelial tumour cells, since 
breast tissue is very heterogeneous and consists of a mixture 
of cells such as tumour cells and surrounding stromal cells. 
To enable large-scale cohort studies, we store microdissected 
samples at -80°C until all tissues have been subjected to LCM. 
Subsequently, proteins are extracted and trypsin digested prior 
to nLC-FTICR or Orbitrap MS analysis. Resulting MS data are 
analysed using Scaffold and Progenesis software, or free-ware 
developed at PNNL, such as DAnTE. The important part of our 
approach is the use of custom-made, ultra-long (50-80 cm), 
narrow diameter (30-75 µm) chromatography columns coupled 
to ultra-high pressure liquid chromatography. We have shown 
that this approach is sensitive enough to identify large numbers 
of proteins from just minute amounts of cells [6]. In addition, 
we identified a putative protein profile that predicted therapy-
resistance in breast cancer patients [7].
Prognosis proteins  We have used the above described tis-
sue proteomics strategy for comparative analysis of 62 triple 
negative breast tumours, of which 22 were from patients with 
poor prognosis and 40 were from patients with good prognosis. 
From each tumour tissue, tryptic digests derived from about 
3,500 cells were analysed. On average, about 1,200 proteins 
were identified per sample, and in total 2,015 proteins were 
identified in all samples with two or more peptides. Initial data 
analysis and unsupervised hierarchical clustering revealed that 
a selection of peptides belonging to 34 proteins is able to sepa-
rate triple negative tumours from patients with poor prognosis 
from those with good prognosis (see Figure 3) [8]. In line with 
our close collaboration with Dr. Ljiljana Paša-Tolić, Ning Qing 
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Figure 3 | Unsupervised hierarchical clustering of triple negative breast 
cancer tissues. Differentially abundant peptides distinguish tumours with 
good and poor prognosis.
Figure 2 | Tissue proteomics work flow. 
Flash frozen tumour tissue is cryosectioned, stained, and subjected to laser 
capture microdissection to specifically isolate tumour cells. Proteins are 
extracted in surfactant and trypsin digested prior to nLC-MS analysis. 
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Summary
Breast cancer is the most commonly diagnosed malignancy in 
women in the Western world, with 13,000 new patients each 
year in the Netherlands alone. Extensive research on gene ex-
pression profiling has shown that breast cancer is a mixture of 
biologically different disease entities, referred to as molecular 
subtypes. Of all molecular subtypes, the triple negative phe-
notype in particular associates with poor prognosis and poor 
patient survival. Intriguingly, only a small subgroup of triple 
negative tumours (25 percent), which metastasize to distant 
organs within three years, accounts for this poor prognosis. 
Currently no clinical markers are available to identify triple 
negative tumours based on positive expression, to predict 
summary
Liu (PhD student supported by NPC) is currently visiting the 
mass spectrometry facility at PNNL for further, detailed analysis 
of his LCM samples. 
Next validation  In conclusion, a fruitful and long-standing 
collaboration with Dr. Paša-Tolić from PNNL has provided a basis 
for establishing sound protocols that enable in-depth com-
parative proteomics studies on clinical cohort samples. In the 
current, NPC funded, project a triple negative breast cancer 
cohort was analysed by nLC-Orbitrap MS and comparative pro-
teome analysis was performed using different software tools. 
Preliminary data showed that patients with poor prognosis could 
be separated from patients with good prognosis based on 34 
differentially abundant proteins. The next step is to investigate 
whether the abundance level of these proteins associates with 
clinical parameters such as patient survival. Most importantly, 
these data will be validated in an independent patient cohort 
before any translation towards the clinic can be made. Once 
validated, our data will provide an additional toolbox for clini-
cians to better predict patient prognosis, pathway analysis of 
key proteins will provide insight into the biology of triple nega-
tive breast cancer, and protein targets will have been identified 
for the development of new and targeted therapies.
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disease prognosis, and against which to target therapy.
The aim of our project was to identify prognostic protein mark-
ers for triple negative breast cancer using a comparative tissue 
proteomics approach. We have subjected frozen breast cancer 
tissue sections to LCM and prepared tryptic digests for nLC-MS 
analysis. Peptide abundance levels from poor prognosis samples 
were compared to good prognosis samples to identify differ-
entially abundant peptides and their corresponding proteins. 
A selection of 34 differentially abundant proteins appeared 
to significantly differentiate between the two groups. Careful 
validation of these proteins may lead to better prediction of 
disease prognosis of triple negative breast cancer patients. 
Furthermore, functional analysis of key proteins may help un-
ravel the biology of triple negative breast cancer and may lead 
to the development of new therapies against target proteins.
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